HTLV-I-associated myelopathy manifested after renal transplantation.
We report a patient with HTLV-I-associated myelopathy (HAM), who developed symptoms of myelopathy 4 years after cadaveric renal transplantation. Since he was seronegative before the transplantation, it is suggested that HTLV-I infection was transmitted via renal graft transplantation. He has been treated with immunosuppressive agents such as cyclosporin A (CsA), mycophenolate mofetil (MMF), and prednisolone (PSL) to prevent graft rejection. This case suggested that these immunosuppressive agents are poorly effective in suppressing either the onset or progression of HAM/TSP.
Nakatsuji
Y
Y
Department of Neurology, Osaka University Graduate School of Medicine, Yamada-oka 2-2, Suita, 565-0871, Osaka, Japan. yuji@neurol.med.osaka-u.ac.jp
Sugai
F
F
Watanabe
S
S
Kaido
M
M
Koguchi
K
K
Abe
K
K
Sakoda
S
S
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015493:Paraparesis, Tropical Spastic / Q000473:pathology* / Q000635:transmission
D007166:Immunosuppressive Agents